|
1) Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-66
|
|
|
|
2) Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008; 10: 162-70
|
|
|
|
|
|
3) Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-8
|
|
|
|
|
|
4) Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010; Epub DOI 10. 1002/cncr. 25256
|
|
|
|
|
|
5) Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-40
|
|
|
|
|
|
6) Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-6
|
|
|
|
|
|
7) Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003; 62: 297-303
|
|
|
|
|
|
8) Zhou YH, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003; 9: 3369-75
|
|
|
|
|
|
9) Rohr U, Augustus S, Lasserre S, et al. Safety of bevacizumab in patients with metastases to the central nervous system [abstract]. J Clin Oncol. 2009; 27: 88s, Abstract 2007
|
|
|
|
|
|
10) Iwamoto FM, Fine HA. Bevacizumab for malignant gliomas. Arch Neurol. 2010; 67: 285-8
|
|
|
|
|
|
11) Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-9
|
|
|
|
|
|
12) Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740-5
|
|
|
|
|
|
13) 永根基雄, 小林啓一, 林 基高, 他. テモゾロミド不応性悪性神経膠腫に対するベバシツマブ単独療法の治療効果. 脳外誌. 2010; 19: 758-66
|
|
|
|
|
|
14) Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95
|
|
|
|
|
|
15) Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-80
|
|
|
|
|
|
16) Wen PY, Macdonald DR, Reardon DA, et al. Updated respnse criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-72
|
|
|
|
|
|
17) Wakai S, Yamakawa K, Manaka S, et al. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery. 1982; 10: 437-44
|
|
|
|
|
|
18) Semrad TJ, OʼDonnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007; 106: 601-8
|
|
|
|
|
|
19) Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009; 252: 182-9
|
|
|
|
|
|
20) Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999; 9: 53-60
|
|
|
|
|
|
21) Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cyto-architecture. Neuroimaging Clin N Am. 2006; 16: 619-32, viii-ix
|
|
|
|
|
|
22) Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2009; 28: e91-3
|
|
|
|
|
|
23) Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009; 9: 444
|
|
|
|
|
|
24) Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009; 5: 610-20
|
|
|
|
|
|
25) Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004; 18: 338-40
|
|
|
|
|
|
26) Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009; 11: 550-5
|
|
|
|
|
|
27) Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008; 7: 1152-60
|
|
|
|
|